Q2 / H1 2024 Results presentation
Andreas Reisse, CEO
Dr. Almuth Steinkühler, CFO
The fiscal year 2024 runs from October 2023 to September 2024.
Disclaimer
This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.
This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.
These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (https://www.schott-pharma.com/investor-relations).
The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.
Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.
For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.
1 © SCHOTT Pharma AG & Co. KGaA
Internal
Strategy & Business Update
Andreas Reisse, CEO
© SCHOTT Pharma AG & Co. KGaA
Based on Q2 2024 results, SCHOTT Pharma is well on track to meet its full year guidance
Revenue1: | EBITDA margin1: | HVS share |
EUR 247m (+11%) | 27.0% | of 53% in H1 2024 |
Continued growth in revenue | Continued high profitability at | Consequent execution of |
despite high basis of | constant currencies while covering | strategy to achieve the mid- |
previous year | significant ramp-up costs | term target of 60% HVS share |
1 At constant currencies
3 © SCHOTT Pharma AG & Co. KGaA
Internal
Robust market trends confirm growth strategy - Continued execution on shift to high-value solutions
Significant market opportunities
- GLP-1
- mRNA
- ADCs
- Subcutaneous administration
- Homecare
- Manufacturing transformation
- ...
Market
Shift to HVS
>60%
53%
Innovation | 48% | |
Trusted | 39% | |
partner |
Expansion
Strategy | FY22 | FY23 | H1 24 | Mid-term |
4 © SCHOTT Pharma AG & Co. KGaA
Internal
SCHOTT Pharma is innovating along the entire value
chain and major pharma megatrends | Innovation | ||||
Advancing large volume infusion
Collaboration with KORU Medical Systems to simplify subcutaneous drug administration
Addresses the market for treatments requiring recurring dosing regimens, e.g., chronic diseases or cancer
Broader functional service offering
One-stop shop for drug developers, covering full range of analytical tests needed for drug submission
Helps customers to accelerate the complex, time- and cost-intensive drug registration process and bring their products to market faster
Pioneering sustainability efforts
Collaborating with Big Pharma to transform industry and advance net zero transformation
Piloting secondary packaging recycling initiatives
5 © SCHOTT Pharma AG & Co. KGaA
Internal
Expansion projects on track: strengthening global presence with new production sites
Expansion
Inauguration of new state-of-the-art production
Successful recent start of commercial production of prefillable glass syringes in Lukacsházá, Hungary
Additional production capacity will support major pharma trends to safely store GLP-1 drugs, vaccines, and biologics
Further investments are planned to expand site
New site in the U.S., one of the strongest growth markets
Investment of USD 371m to increase manufacture capabilities for HVS
First U.S. manufacturing facility in Wilson, North Carolina, to fill demand for domestic supply of prefillable glass and polymer syringes
Groundbreaking expected for 2025
6 © SCHOTT Pharma AG & Co. KGaA
Internal
Financial Update
Dr. Almuth Steinkühler, CFO
© SCHOTT Pharma AG & Co. KGaA
Key financial figures for Q2 2024
RevenuesEBITDAMargin
EUR 247m (cc1) | 11% | EUR 67m (cc1) | 27.0% |
EUR 234m (rep.) | 5% | EUR 44m (rep.) | 18.9% |
CAPEX2 | EPS | ||
EUR 28m | - 5m | EUR 0.17 | - 48% |
1 At constant currencies; 2 Capex excluding leasing
8 © SCHOTT Pharma AG & Co. KGaA
Internal
Strong revenue growth despite high comparable base from previous year
Revenues1 | DCS | DDS | |
EURm | |||
+9% | |||
+11% | (cc2) | ||
(cc2) | +4% | ||
(rep.) | (rep.) | 489 | |
+5% | |||
(rep.) | 449 | ||
247 | |||
224 |
96 | 155 | 200 | |
72 | |||
151 | 151 | 294 | 290 |
Q2 23 | Q2 242 | H1 23 | H1 242 |
1 Segment split excluding consolidation effects, 2 At constant currencies
9 © SCHOTT Pharma AG & Co. KGaA
Key developments
Strong demand for prefillable syringes and the ongoing expansion of capacities in DDS segment leads to further increase of HVS
DCS segment developed as expected and returned to high level of previous year despite the temporary destocking effect for vials on the customer side
Internal
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Schott Pharma AG & Co. KGaA published this content on 27 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2024 07:58:05 UTC.